Table 4 Median pre-treatment and treatment costs in tuberculosis patients diagnosed through active case finding (ACF) and passive case finding (PCF), Nepal, 2018
Cost item | ACF (n = 50) | PCF (n = 49) | Total (n = 100) | P-valueb |
|---|---|---|---|---|
Pre-treatment period | Median (IQR) | Median (IQR) | Median (IQR) | |
Direct medical | ||||
Consultation fee | 0.0 (0.0–0.1) | 0.2 (0.0–4.5) | 0.0 (0.0–1.0) | 0.003 |
Radiography | 0.5 (0.0–3.2) | 3.2 (0.0–9.9) | 1.6 (0.0–5.6) | 0.003 |
Lab tests | 1.1 (0.0–3.4) | 2.7 (0.0–5.7) | 1.8 (0.0–4.1) | 0.092 |
Medicines | 5.9 (0.0–16.8) | 18.3 (1.5–36.7) | 8.1 (0.5–25.6) | 0.021 |
Other medical | 0.0 (1.8–4.5) | 3.3 (1.4–6.6) | 2.7 (0.0–5.8) | 0.013 |
Total direct medical | 14.3 (4.5–27.7) | 31.6 (11.0–79.1) | 19.2 (6.3–46.3) | 0.001 |
Direct non-medical | ||||
Transportation | 3.3 (0.9–7.2) | 5.4 (1.8–15.5) | 3.7 (1.8–10.4) | 0.031 |
Food | – | 0.0 (0.0–10.8) | 0.0 (0.0–2.7) | 0.006 |
Total direct non-medical | 3.4 (1.8–10.4) | 9.7 (2.7–37.9) | 5.4 (2.1–22.4) | 0.004 |
Indirect | ||||
Time lossa | 4.4 (1.9–8.1) | 13.4 (5.6–21.8) | 7.8 (3.7–15.0) | < 0.001 |
Income loss | 51.4 (0.0–240.1) | 30.7 (0.0–201.8) | 40.6 (0.0–212.9) | 0.629 |
Total indirect | 63.5 (5.0–255.1) | 43.3 (14.3–248.2) | 51.1 (8.4–251.6) | 0.430 |
Total cost pre-treatment | 132.3 (22.6–258.0) | 172.3 (59.9–405.4) | 147.3 (41.6–304.9) | 0.103 |
Intensive phase | ||||
Direct medical | ||||
Consultation fee/charges | – | – | – | – |
Radiography/lab tests | – | – | – | – |
Medicines | – | 0.0 (0.0–1.8) | – | 0.045 |
Total direct medical | – | 0.0 (0.0–4.0) | – | 0.070 |
Direct non-medical | ||||
Transportation | 0.0 (0.0–7.2) | 0.4 (0.0–17.3) | 0.0 (0.0–8.5) | 0.041 |
Food | 0.0 (0.0–6.8) | 0.0 (0.0–19.5) | 0.0 (0.0–7.7) | 0.547 |
Total direct non-medical | 0.0 (0.0–14.4) | 1.3 (0.0–44.8) | 0.0 (0.0–28.0) | 0.034 |
Indirect | ||||
Time lossa | 29.9 (15.0–44.9) | 31.0 (11.7–59.8) | 29.9 (15.0–56.1) | 0.816 |
Income loss | 18.1 (0.0–49.7) | 9.6 (0.0–45.2) | 17.1 (0.0–45.2) | 0.377 |
Total indirect | 54.9 (29.9–95.9) | 59.6 (34.9–82.7) | 55.1 (29.9–90.5) | 0.817 |
Other | ||||
Nutritional supplements | 13.6 (7.5–25.4) | 15.5 (9.3–35.3) | 14.9 (8.1–27.8) | 0.404 |
Total costs intensive phase | 84.7 (56.1–144.0) | 103.7 (45.3–193.2) | 96.6 (51.8–176.9) | 0.557 |
Total cost pre-treatment and intensive phase | ||||
Total direct medical costs | 14.9 (4.5–46.1) | 34.1 (13.1–87.5) | 22.6 (6.7–63.8) | 0.002 |
Total direct non-medical costs | 29.6 (15.6–55.1) | 54.0 (21.5–124.6) | 37.5 (17.8–83.5) | 0.022 |
Total direct costs | 40.2 (26.1–91.7) | 114.9 (45.3–250.5) | 68.5 (31.7–148.6) | 0.001 |
Total indirect costs | 128.2 (34.9–357.4) | 106.1 (57.8–340.9) | 112.4 (52.4–343.7) | 0.942 |
Total c | 252.8 (80.9–452.8) | 315.3 (125.8–543.9) | 290.1 (88.7–476.7) | 0.161 |